Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.79 |
| ▸ | DDX3X | O00571 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 8/20 | 0.53 |
| ▸ | RAB9A | P51151 | 7/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | PKM | P14618 | 2/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | GRB7 | Q14451 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3766427 | 0.88 | AKR1C3 (1.00) | AKR1C3DDX3XMTORHDAC11NPC1 | |
| SCHEMBL20096879 | 0.87 | AKR1C3 (0.75) | AKR1C3DDX3XLMNAHDAC11NPC1 | |
| SCHEMBL254593 | 0.87 | AKR1C3 (0.79) | AKR1C3DDX3XMTORHDAC11NPC1 | |
| SCHEMBL13002087 | 0.86 | AKR1C3 (0.73) | AKR1C3DDX3XLMNAMTORHDAC11 | |
| SCHEMBL22703577 | 0.86 | AKR1C3 (0.73) | AKR1C3DDX3XLMNAMTORHDAC11 | |
| SCHEMBL29624703 | 0.86 | AKR1C3 (0.77) | AKR1C3DDX3XHDAC11NPC1RAB9A | |
| SCHEMBL20096686 | 0.86 | AKR1C3 (0.77) | AKR1C3DDX3XHDAC11NPC1RAB9A | |
| SCHEMBL13058906 | 0.85 | MEN1 (0.62) | AKR1C3DDX3XLMNANPC1RAB9A | |
| SCHEMBL32666086 | 0.84 | MAPT (0.65) | AKR1C3LMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL18236256 | 0.79 | AKR1C3 (0.63) | AKR1C3DDX3XLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3453711-B1 | LLP2A- BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2021-08-18 | — | — | EP | disclosed |
| EP-2753626-B1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | UNIV CALIFORNIA (US) | 2018-08-08 | — | — | EP | disclosed |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-06-22 | — | — | US | disclosed |
| US-9561256-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2017-02-07 | — | — | US | disclosed |
| US-9119884-B2 | LLP2A-bisphosphonate conjugates for osteoporosis treatment | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-09-01 | — | — | US | disclosed |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-02-27 | — | — | US | disclosed |
| US-8486370-B2 | Heterocyclic ligands for integrin imaging and therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310455-A1 | Heterocyclic Ligands for Integrin Imaging and Therapy | ITGA1, ITGAL, ITGA4 | AKR1C3 4531/4885DDX3X 3524/4885LMNA 2248/4885 |
| US-20170174722-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | AKR1C3 3922/4885DDX3X 4223/4885LMNA 1950/4885 |
| US-20140056855-A1 | LLP2A-BISPHOSPHONATE CONJUGATES FOR OSTEOPOROSIS TREATMENT | LCP1, BST2, ITGA2B | AKR1C3 3922/4885DDX3X 4223/4885LMNA 1950/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.